Rein Therapeutics, Inc. (RNTX): Depreciation & Amortization
$1.0K
Year ended 2025-12-31
$0
Trailing 12 months to 2026-06-30
-81.9%
3-year compound annual growth
-63.9%
5-year compound annual growth
-43.9%
10-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.0K | -98.4% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $63.0K | -47.1% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $119.0K | -29.6% | 2025-04-07, From 2023-01-01 |
| 2022-12-31 | $169.0K | +39.7% | 2024-04-15, From 2022-01-01 |
| 2021-12-31 | $121.0K | -25.8% | 2023-03-20, From 2021-01-01 |
| 2020-12-31 | $163.0K | +5.2% | 2022-03-28, From 2020-01-01 |
| 2019-12-31 | $155.0K | -28.9% | 2021-03-24, From 2019-01-01 |
| 2018-12-31 | $218.0K | +69.0% | 2020-03-30, From 2018-01-01 |
| 2017-12-31 | $129.0K | -44.4% | 2019-03-29, From 2017-01-01 |
| 2016-12-31 | $232.0K | -28.6% | 2018-04-02, From 2016-01-01 |
| 2015-12-31 | $325.0K | n/a | 2018-04-02, From 2015-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Rein Therapeutics, Inc. (RNTX) | 2025-12-31 | $1.0K | -98.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $4.01B | -58.2% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $384.0K | -24.6% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $2.00B | +13.0% |
| Pfizer Inc (PFE) | 2025-12-31 | $6.59B | -6.0% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $7.50B | +2.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $13.84M | -2.6% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $146.0K | -16.1% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $2.31M | -7.1% |
Compare RNTX, BMY, TXMD, LLY side by side · Screen every company in Pharmaceutical Preparations ↗